How long should I avoid ejaculation before a repeat PSA test, and should I take antibiotics first?

Abstain from ejaculation for 48 hours before your blood draw (`97%` of men return to baseline by 48 hours), and skip heavy cycling or vigorous workouts for 48 hours as a simple precaution. 1 7 Do not take empiric antibiotics for a high PSA unless you have clear symptoms or lab proof of a urinary tract infection or acute prostatitis (`AUA 2026` and `EAU 2026` guidelines). 1 19

Does `1 mg` finasteride for hair loss (`Propecia`) affect my PSA result?

Yes, just as strongly as the `5 mg` prostate dose. In a randomized trial (`D'Amico & Roehrborn, Lancet Oncology 2007`), `1 mg/day` of finasteride cut PSA by 40% at ages 40 to 49 and 50% at ages 50 to 60. 14 Fishtown Medicine doubles your printed PSA (`x2.0`, and `x2.3 to 2.5` after 7+ years on finasteride) before comparing it to our ` = 0.3 ng/mL` above your lowest on-treatment number (`nadir`). 16 17

How long should I avoid ejaculation before a repeat PSA test, and should I take antibiotics first?

Abstain from ejaculation for 48 hours before your blood draw (`97%` of men return to baseline by 48 hours), and skip heavy cycling or vigorous workouts for 48 hours as a simple precaution. 1 7 Do not take empiric antibiotics for a high PSA unless you have clear symptoms or lab proof of a urinary tract infection or acute prostatitis (`AUA 2026` and `EAU 2026` guidelines). 1 19

Does `1 mg` finasteride for hair loss (`Propecia`) affect my PSA result?

Yes, just as strongly as the `5 mg` prostate dose. In a randomized trial (`D'Amico & Roehrborn, Lancet Oncology 2007`), `1 mg/day` of finasteride cut PSA by 40% at ages 40 to 49 and 50% at ages 50 to 60. 14 Fishtown Medicine doubles your printed PSA (`x2.0`, and `x2.3 to 2.5` after 7+ years on finasteride) before comparing it to our ` = 0.3 ng/mL` above your lowest on-treatment number (`nadir`). 16 17

Elevated PSA: What Raises It, How to Repeat It, When to See Urology

TL;DR30-second take

A high PSA is common and frequently not cancer: roughly 30% of values above 4.0 ng/mL return to normal on the next test (and 38% at age 45 in PROBASE). Ejaculation within 24 to 48 hours (+41% rise at 1 hour), urinary tract infection or prostatitis (5- to 7-fold rise), recent catheterization or instrumentation, and benign enlargement (BPH) all push PSA up, while finasteride (even 1 mg for hair loss) and dutasteride cut PSA in half. The modern guideline pathway (AUA 2026, EAU 2026, NCCN 2026) repeats the draw after a 48-hour washout without empiric antibiotics, checks percent free PSA and PSA density (<0.15 ng/mL/cc), and uses prostate MRI before biopsy to avoid 25% to 50% of biopsies.

TL;DR: Seeing a high PSA on your lab report is stressful, yet a single high reading is frequently not cancer. Across large studies, 22% to 38% of high PSAs drop back to normal on the next blood draw. Before anyone talks about a prostate biopsy, follow this 4-step triage sequence (AUA 2026, EAU 2026, and NCCN 2026 guidelines):

Check whether a medication is masking an even higher number (the 5-ARI rule): If you take finasteride (1 mg for hair loss or 5 mg for BPH) or dutasteride (0.5 mg), your printed PSA is cut in half (~40% to 50%). You must double your printed PSA before comparing it against our age cutoffs (< 2.5 ng/mL under age 60; < 4.0 ng/mL at age 60+), and evaluate any confirmed rise (>= 0.3 ng/mL) above your lowest on-treatment number.

Repeat the PSA in 4 to 8 weeks after a 48-hour washout (and skip empiric antibiotics): Abstain from ejaculation for 48 hours before the draw (and take 48 hours off heavy cycling or pelvic pressure as a zero-cost precaution). If you had a recent UTI or prostatitis, wait 6 to 8 weeks after it clears. Guidelines explicitly advise against taking antibiotics for a symptom-free high PSA.

Add Percent Free PSA (%fPSA) on the repeat draw: When total PSA is 4 to 10 ng/mL, a free PSA ratio above 25% drops cancer probability to 8%, whereas a ratio of 10% or under raises it to 56%.

Use a 3-Tesla prostate MRI + PSA density (PSAD < 0.15 ng/mL/cc) before any biopsy: If your repeat PSA stays high, an MRI-first workup (PRECISION and GÖTEBORG-2 trials) lets 25% to 50% of men avoid a biopsy, cuts harmless Grade Group 1 overdiagnosis in half, and targets the biopsy if one is needed.

Three-step triage pathway for a high PSA: midlife baseline medians and Fishtown cutoffs, the finasteride/dutasteride 5-ARI doubling and nadir rules plus 48-hour repeat washout, and pre-biopsy MRI with PSA density — The evidence-based sequence when a PSA comes back high: check 5-ARI medications, repeat after a 48-hour washout, and combine MRI with PSA density before considering biopsy.

What does a high PSA number mean for your risk?

PSA (prostate-specific antigen) is a protein made by normal prostate cells as well as cancer cells. A small amount always circulates in the blood, and the level rises whenever the prostate is enlarged, inflamed, recently stimulated, or harboring a tumor.¹

Standard lab reports flag PSA at 4.0 ng/mL regardless of age, which misses how strongly healthy PSA levels depend on your decade of life:

In your 40s and 50s (Malmö Preventive Project, Vickers et al., BMJ 2013, n = 21,277): The population median PSA is 0.68 ng/mL at ages 45 to 49, 0.85 ng/mL at ages 51 to 55, and ~1.0 ng/mL at age 60.² ³ Men in the highest 10% (>= 1.6 ng/mL at ages 45 to 49, or >= 2.4 ng/mL at ages 51 to 55) account for 44% of all future prostate cancer deaths.²
Fishtown Medicine's age-adjusted cutoffs: Because 4.0 ng/mL is too loose for a man in his 40s or 50s, Fishtown Medicine uses a target of under 2.5 ng/mL for men under age 60 and under 4.0 ng/mL at age 60 and older.¹
What a PSA between 4 and 10 ng/mL means: Historically, a single PSA between 4 and 10 ng/mL carried roughly a 25% to 35% chance of finding any prostate cancer on biopsy, and more than half of those findings were slow-growing Grade Group 1 (Gleason 6) tumors that never would have threatened the man's life.¹ ⁴

What raises (or falsely lowers) PSA besides prostate cancer?

Before assuming a high PSA comes from a tumor, we check five non-cancer factors that move the number, including one common medication class that hides a high PSA in plain sight:¹

Factor	Quantified Effect on `PSA` in Clinical Studies	Practical Rule Before Your Next Draw
Febrile UTI or acute prostatitis (`Ulleryd 1999`; `Zackrisson 2003`)	Raises PSA 5- to 7-fold in `71% to 83%` of cases; can stay high with a low free/total ratio for up to 6 months.⁵ ⁶	Never test PSA during a urinary infection. Wait 6 to 8 weeks after an infection resolves. Do not take empiric antibiotics for an asymptomatic high PSA (`AUA 2026`).¹
Recent ejaculation (`Tchetgen et al., Urology 1996`)	Raises PSA by a mean `+41%` at 1 hour; returns to baseline in `92%` of men by 24 hours and `97%` by 48 hours (the `AUA` notes average population changes of `~10%`).¹ ⁷	Abstain from ejaculation for 48 hours before your blood draw.¹ ⁷
Prostate biopsy, TURP, or catheterization (`Oesterling 1993`; `Wong et al., World J Urol 2026` SR)	Biopsy or TURP raises PSA by a median `5.9 to 7.9 ng/mL` for `4+` weeks; urethral catheterization adds `+0.69 ng/mL` (`+0.28` without retention).⁸ ⁹	Wait at least 6 weeks after a biopsy/TURP and 2 to 6 weeks after catheter removal.⁸ ⁹ (A routine finger exam / `DRE` adds only `+0.4 ng/mL`, which is clinically trivial unless measuring free PSA.)¹⁰
Vigorous cycling or pelvic pressure (`Jiandani et al., 2015` meta-analysis, `n = 912`; `Lunacek 2022` RCT)	Pooled change across 6 studies was `+0.027 ng/mL` (`P = 0.74`), much smaller than once thought, and the `AUA 2026` guideline notes cycling does not appreciably alter PSA.¹ ¹¹	While cycling rarely explains a high PSA on its own, skipping heavy bike rides or marathon saddle time for 48 hours before a repeat draw is an easy, zero-cost precaution.¹
Benign prostate enlargement (`BPH`)	More benign gland tissue leaks more baseline PSA into the blood with age.	Separated from cancer risk by calculating PSA density (`PSAD = PSA / gland volume < 0.15 ng/mL/cc`) on ultrasound or MRI.¹ ¹²
Finasteride (`1 mg` hair loss / `5 mg` BPH) & Dutasteride (`0.5 mg`) (`PCPT`, `REDUCE`, `D'Amico 2007`)	Cuts PSA in half (`-40% to -50%`) after 6 to 12 months by shrinking gland tissue and blocking `DHT` gene transcription.¹³ ¹⁴ ¹⁵	Multiply your printed PSA by `2.0x` (`x2.3 to 2.5` after 7+ years on finasteride) AND evaluate any confirmed rise `>= 0.3 ng/mL` above your lowest on-treatment number (`nadir`).¹³ ¹⁶ ¹⁷

Why hair-loss finasteride (`1 mg`) is the most dangerous blind spot on a PSA report

In a randomized trial (D'Amico & Roehrborn, Lancet Oncology 2007), taking just 1 mg/day of finasteride (Propecia) for male-pattern hair loss lowered PSA by 40% in men aged 40 to 49 and 50% in men aged 50 to 60, matching the 5 mg prostate dose (Proscar) in the PCPT trial (n = 18,882) and dutasteride 0.5 mg in the REDUCE trial (n = 8,231).¹³ ¹⁴ ¹⁵

If you take finasteride or dutasteride and your doctor reads a PSA of 2.1 ng/mL as "normal" without doubling it to 4.2 ng/mL, a clinically significant rise gets missed. In a national cohort study (Sarkar et al., JAMA Internal Medicine 2019), men on 5-ARIs whose PSAs were not adjusted suffered delayed diagnostic biopsies and a 39% higher risk of prostate cancer death (HR 1.39).¹⁸ Even more important: in PCPT, any confirmed rise (>= 0.3 ng/mL) above a man's lowest on-treatment PSA (nadir) tripled overall cancer risk and increased high-grade cancer risk 6-fold, even when the doubled number was still below 4.0 ng/mL.¹⁷

How should you repeat a high PSA test?

Both the American Urological Association (AUA/SUO 2026), the European Association of Urology (EAU 2026), and NCCN (v2.2026) state that the first step after an unexpected high PSA is repeating the blood test in 4 to 8 weeks before ordering expensive biomarkers, an MRI, or a biopsy.¹ ¹⁹

Why? Because spontaneous year-to-year and month-to-month biological fluctuation is huge:

Memorial Sloan Kettering (Eastham et al., JAMA 2003): 30% of men with a PSA above 4.0 ng/mL had a normal PSA on their next test, and 44% normalized at some point over 4 years.²⁰
PLCO Trial (Pickersgill et al., JAMA Oncology 2025): 22% to 30% of values above threshold fell back below it within 1 year.²¹
PROBASE Trial (Krilaviciute et al., Eur Urol 2026): Among 45-year-old men, 38% normalized on confirmatory testing.²²
STHLM3 Trial: 17% of men with a PSA between 3 and 10 ng/mL dropped below 3.0 ng/mL within 8 weeks.¹

Your 4-point checklist for the repeat blood draw

Wait 4 to 8 weeks (or 6 to 8 weeks if you recently finished treatment for a UTI or prostatitis, or had a catheter/procedure).¹ ⁵
Abstain from ejaculation for 48 hours before the blood draw, and skip heavy cycling or intense workouts for 48 hours as a simple precaution.¹ ⁷
Ask your doctor to order Total PSA + Percent Free PSA (%fPSA) on the same tube (at the same lab chain, Quest or LabCorp, so the assay calibration matches).
If the repeat PSA drops back below target, do not disappear from follow-up: In longitudinal tracking (Connolly et al., 2008), roughly 25% of men whose PSA fell back below 4.0 ng/mL were eventually diagnosed with prostate cancer on later draws.²³ If your repeat normalizes, we recheck PSA in 6 to 12 months to confirm it stays down.

Fishtown Medicine

A 90-minute conversation with Dr. Ash. A written plan you can follow.

Start your intake

What happens if your repeat PSA stays high (`%fPSA`, `PSAD`, and `MRI`)?

When a properly repeated PSA remains above target, and sooner if you are under age 55, a Black man, have a family history of prostate cancer, or have an abnormal prostate exam, the modern workup uses three filters before any biopsy needle is considered:¹ ¹⁹

Percent Free PSA (%fPSA, Catalona et al., JAMA 1998): Prostate cancer cells bind more PSA to blood proteins (ACT), leaving a smaller percentage of "free" (unbound) PSA floating in the bloodstream. For men with a total PSA between 4 and 10 ng/mL and a normal exam, cancer probability is 56% when %fPSA <= 10%, versus only 8% when %fPSA > 25% (AUC 0.72 vs 0.53 for total PSA alone, avoiding 20% of biopsies at 95% sensitivity; note that a 25% cutoff is less sensitive in Black men, Fowler 2000).²⁴ ²⁵ Crucially, %fPSA is not altered by finasteride or dutasteride.¹⁷
3-Tesla Prostate MRI (PROMIS, PRECISION, GÖTEBORG-2): Instead of sampling the gland blindly, a prostate MRI looks for discrete lesions and grades them from 1 (very low suspicion) to 5 (very high suspicion).⁴²⁶²⁷ Across randomized trials (high certainty for reducing biopsies and GG1 overdiagnosis; moderate certainty for GG >= 2 detection):
- In PRECISION (Kasivisvanathan et al., NEJM 2018, n = 500), MRI first allowed 28% of men to avoid biopsy, cut overdiagnosis of indolent Grade Group 1 (Gleason 6) tumors by 59% relative (9% vs 22%, -13 percentage points absolute), and caught more aggressive Grade Group >= 2 tumors (38% vs 26%, +12 percentage points absolute).⁴
- In GÖTEBORG-2 (Hugosson et al., NEJM 2024, n = 17,980, 4-year follow-up), MRI triage reduced biopsy indications by 59% to 74% and cut Grade Group 1 overdiagnosis by 57% (RR 0.43).²⁷
PSA Density (PSAD < 0.15 ng/mL/cc): Using the prostate volume measured on your MRI, we divide your total PSA by gland volume (ng/mL/cc). When a negative MRI (PI-RADS 1-2) is combined with a PSAD < 0.15 ng/mL/cc, the negative predictive value for clinically significant (GG >= 2) cancer climbs from 84.4% to 90.4% to 94% (Pagniez et al., J Urol 2020; AUA 2026), allowing up to two-thirds of men with a negative MRI to safely skip immediate biopsy while staying on regular PSA monitoring (GÖTEBORG-2 showed a 5.5% 7-year GG >= 2 incidence after a negative MRI with PSAD < 0.10, versus 11.9% to 13.8% when PSAD was higher).¹ ²⁸ ²⁹
Transperineal Targeted Biopsy (when biopsy is needed): If your MRI shows a PI-RADS 4 or 5 lesion (or PI-RADS 3 with high PSAD), we coordinate an MRI-targeted biopsy with in-network urology and favor the transperineal approach over the older transrectal approach. Across randomized trials (TRANSLATE, Bryant et al., Lancet Oncol 2025) and a 2026 meta-analysis (Calpin et al., BJU Int 2026), transperineal biopsy lowers post-biopsy sepsis risk by 84% (RR 0.16) (1.0% vs 1.4% sepsis readmission vs 5% to 7% historical transrectal infection rates, with a minor 1.9% vs 1.0% temporary urinary retention trade-off).³⁰ ³¹

Guidance from the Clinic

"When a patient messages me that his PSA came back high, the first three questions I ask are: Did you ejaculate in the 48 hours before the draw? Have you had any urinary burning or infection recently? And are you taking finasteride for your hair or prostate? Almost a third of high PSAs drop right back into range on a repeat draw 4 to 6 weeks later. And when a repeat stays up, particularly in a man under 55 or a Black man, we add free PSA and a 3-Tesla prostate MRI with PSA density first, so we never send someone to a blind biopsy if an MRI can spare them."

Key Takeaways

Roughly `22% to 38%` of high PSAs return to normal on repeat testing (`Eastham JAMA 2003`; `PROBASE 2026`), so always repeat an unexpected high reading in 4 to 8 weeks before jumping to biopsy.²⁰ ²²
Abstain from ejaculation for 48 hours before your repeat draw (`+41%` 1-hour rise) and wait 6 to 8 weeks after any UTI or prostatitis (`5- to 7-fold` rise); never take empiric antibiotics for a symptom-free high PSA.¹ ⁵ ⁷
Finasteride (`1 mg` hair loss or `5 mg` BPH) and dutasteride (`0.5 mg`) cut PSA by `~40% to 50%`: Double your printed PSA (`x2.0`, or `x2.3 to 2.5` after 7+ years) and evaluate any confirmed rise `>= 0.3 ng/mL` above your on-treatment nadir.¹³ ¹⁴ ¹⁶ ¹⁷
Use Percent Free PSA (`%fPSA`), PSA Density (`PSAD < 0.15 ng/mL/cc`), and 3-Tesla MRI before biopsy (`PRECISION`, `GÖTEBORG-2`): Spares `25% to 50%` of men from biopsy and cuts `Grade Group 1` overdiagnosis in half.⁴ ²⁴ ²⁷ ²⁸

PSA and Prostate Cancer Screening - midlife baseline medians (0.68 at age 45-49), ERSPC 23-year mortality data, and who should screen early
Enlarged Prostate (BPH) - treating urinary symptoms and understanding how 5-ARIs change PSA
Why We Choose an MRI - what a multiparametric prostate MRI involves
Paying Cash for Care - why doing the inexpensive repeat PSA draw first saves thousands on unnecessary imaging
Metabolic Health Beyond A1c - how insulin resistance links to prostate enlargement and aggressive disease

Scientific References

Wei JT, Barocas D, Carlsson S, et al. "Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening." The Journal of Urology. 2023;210(1):46-53 (amended 2026). PMC
Vickers AJ, Ulmert D, Sjoberg DD, et al. "Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study." BMJ. 2013;346:f2023. PubMed
Vickers AJ, Cronin AM, Björk T, et al. "Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study." BMJ. 2010;341:c4521. PubMed
Kasivisvanathan V, Rannikko AS, Borghi M, et al. "MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis" (PRECISION). New England Journal of Medicine. 2018;378(19):1767-1777. DOI
Ulleryd P, Zackrisson B, Aus G, et al. "Prostatic Involvement in Men With Febrile Urinary Tract Infection as Measured by Serum Prostate-Specific Antigen and Transrectal Ultrasonography." BJU International. 1999;84(4):470-474. PubMed
Zackrisson B, Ulleryd P, Aus G, et al. "Evolution of Free, Complexed, and Total Serum Prostate-Specific Antigen and Their Ratios During 1 Year of Follow-Up of Men With Febrile Urinary Tract Infection." Urology. 2003;62(2):278-281. PubMed
Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. "Ejaculation Increases the Serum Prostate-Specific Antigen Concentration." Urology. 1996;47(4):511-516. PubMed
Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. "Effect of Cystoscopy, Prostate Biopsy, and Transurethral Resection of Prostate on Serum Prostate-Specific Antigen Concentration." Urology. 1993;42(3):276-282. PubMed
Wong HPN, Lau RS, Kyaw L, et al. "Elevated prostate specific antigen due to indwelling urethral catheterisation: myth or fact? A systematic review and meta-analysis." World Journal of Urology. 2026. DOI
Chybowski FM, Bergstralh EJ, Oesterling JE. "The Effect of Digital Rectal Examination on the Serum Prostate Specific Antigen Concentration: Results of a Randomized Study." The Journal of Urology. 1992;148(1):83-86. PubMed
Jiandani D, Randhawa A, Brown RE, et al. "The effect of bicycling on PSA levels: a systematic review and meta-analysis." Prostate Cancer and Prostatic Diseases. 2015;18(3):208-212. DOI
Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh NJ. "The use of prostate specific antigen density to predict clinically significant prostate cancer." Scientific Reports. 2020;10(1):20015. DOI
Thompson IM, Goodman PJ, Tangen CM, et al. "The Influence of Finasteride on the Development of Prostate Cancer" (PCPT). New England Journal of Medicine. 2003;349(3):215-224. DOI
D'Amico AV, Roehrborn CG. "Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial." The Lancet Oncology. 2007;8(1):21-25. PubMed
Andriole GL, Bostwick DG, Brawley OW, et al. "Effect of Dutasteride on the Risk of Prostate Cancer" (REDUCE). New England Journal of Medicine. 2010;362(13):1192-1202. DOI
Etzioni RD, Howlader N, Shaw PA, et al. "Long-Term Effects of Finasteride on Prostate Specific Antigen Levels: Results From the Prostate Cancer Prevention Trial." The Journal of Urology. 2005;174(3):877-881. PubMed
Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. "The Interpretation of Serum Prostate Specific Antigen in Men Receiving 5alpha-Reductase Inhibitors: A Review and Clinical Recommendations." The Journal of Urology. 2006;176(3):868-874. PubMed
Sarkar RR, Parsons JK, Bryant AK, et al. "Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer." JAMA Internal Medicine. 2019;179(6):812-819. DOI
Cornford P, van den Bergh RCN, Briers E, et al. "EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer - 2026 Update. Part I: Screening, Diagnosis, and Local Treatment With Curative Intent." European Urology. 2026. PubMed
Eastham JA, Riedel E, Scardino PT, et al. "Variation of Serum Prostate-Specific Antigen Levels: An Evaluation of Year-to-Year Fluctuations." JAMA. 2003;289(20):2695-2700. DOI
Pickersgill NA, Peré MM, Vertosick EA, et al. "Prostate-Specific Antigen Levels Among Participants Receiving Annual Testing." JAMA Oncology. 2025. DOI
Krilaviciute A, Becker N, Carlsson SV, et al. "Confirmation of Prostate-Specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-Aged Men - Data From the PROBASE Trial." European Urology. 2026. PubMed
Connolly D, Black A, Murray LJ, et al. "Repeating an Abnormal Prostate-Specific Antigen (PSA) Level: How Relevant Is a Decrease in PSA?" Prostate Cancer and Prostatic Diseases. 2008;11(1):64-68. PubMed
Catalona WJ, Partin AW, Slawin KM, et al. "Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial." JAMA. 1998;279(19):1542-1547. DOI
Fowler JE, Sanders J, Bigler SA, et al. "Percent Free Prostate Specific Antigen and Cancer Detection in Black and White Men With Total Prostate Specific Antigen 2.5 to 9.9 ng/mL." The Journal of Urology. 2000;163(5):1467-1470. PubMed
Ahmed HU, El-Shater Bosaily A, Brown LC, et al. "Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study." The Lancet. 2017;389(10071):815-822. PubMed
Hugosson J, Godtman RA, Wallstrom J, et al. "Results after Four Years of Screening for Prostate Cancer with PSA and MRI" (GÖTEBORG-2). New England Journal of Medicine. 2024;391(12):1083-1095. DOI
Pagniez MA, Kasivisvanathan V, Puech P, et al. "Predictive Factors of Missed Clinically Significant Prostate Cancers in Men With Negative Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis." The Journal of Urology. 2020;204(1):24-32. PubMed
Möller F, Månsson M, Hellström M, et al. "The Role of PSA Density in the Follow Up of Men With a Negative MRI in the Göteborg-2 Trial." BJU International. 2026. PubMed
Calpin GG, Hehir CM, Alzayer M, et al. "Transrectal vs Transperineal Prostate Biopsy: A Systematic Review and Meta-Analysis." BJU International. 2026. PubMed
Bryant RJ, Marian IR, Williams R, et al. "Local Anaesthetic Transperineal Biopsy Versus Transrectal Prostate Biopsy in Prostate Cancer Detection (TRANSLATE): A Multicentre, Randomised, Controlled Trial." The Lancet Oncology. 2025. PubMed
Preston MA, Gerke T, Carlsson SV, et al. "Baseline Prostate-Specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men." European Urology. 2019;75(3):399-407. PubMed

Fishtown Medicine | Diagnostics

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

No. Roughly 30% of men with a PSA above `4.0 ng/mL` return to normal on their next blood test (`Eastham et al., JAMA 2003`; `38%` at age 45 in `PROBASE 2026`), and among men whose PSA stays between `4 and 10 ng/mL`, roughly two-thirds to three-quarters do not have cancer on biopsy.2022 Benign prostate enlargement (`BPH`), ejaculation within 24 to 48 hours (`+41%` rise at 1 hour), and urinary tract infections or prostatitis (`5- to 7-fold` rise) are common non-cancer causes.57

Abstain from ejaculation for 48 hours before your blood draw (`97%` of men return to baseline by 48 hours), and skip heavy cycling or vigorous workouts for 48 hours as a simple precaution.17 Do not take empiric antibiotics for a high PSA unless you have clear symptoms or lab proof of a urinary tract infection or acute prostatitis (`AUA 2026` and `EAU 2026` guidelines).119

Yes, just as strongly as the `5 mg` prostate dose. In a randomized trial (`D'Amico & Roehrborn, Lancet Oncology 2007`), `1 mg/day` of finasteride cut PSA by 40% at ages 40 to 49 and 50% at ages 50 to 60.14 Fishtown Medicine doubles your printed PSA (`x2.0`, and `x2.3 to 2.5` after 7+ years on finasteride) before comparing it to our `< 2.5 ng/mL` (under age 60) and `< 4.0 ng/mL` (age 60+) cutoffs, and evaluates any confirmed rise `>= 0.3 ng/mL` above your lowest on-treatment number (`nadir`).1617

Rarely on its own. While older advice blamed bike saddles and long drives for many high PSAs, a 6-study meta-analysis (`Jiandani et al., 2015`, `n = 912`) found cycling changed PSA by only `+0.027 ng/mL` (`P = 0.74`), and the `AUA 2026` guideline notes cycling does not appreciably alter PSA.111 Skipping long rides for 48 hours before a repeat draw is still a fine zero-cost precaution, but ejaculation (`+41%`), urinary infection (`5- to 7-fold`), or benign gland growth (`BPH`) are far more likely culprits.57

Yes. Black men develop prostate cancer earlier and have higher rates of aggressive disease. In the Southern Community Cohort (`Preston et al., European Urology 2019`), 95% of all prostate cancers and 97% of aggressive cancers in Black men occurred when midlife baseline PSA was above the age median (`0.68 ng/mL` in the late 40s).32 Guidelines recommend starting baseline screening at age 40 to 45 (`AUA 2026 Strong recommendation, Grade B`), and a persistently high PSA in a Black man in his 40s or 50s warrants prompt MRI and urology evaluation.132

Deep-Dive Questions

PSA density divides your total PSA (`ng/mL`) by the volume of your prostate (`cc` or `mL`) measured on MRI. Because a large benign gland produces more background PSA, a `PSAD` below `0.15 ng/mL/cc` points toward benign enlargement (`BPH`), whereas `>= 0.15 ng/mL/cc` points toward higher risk of `Grade Group >= 2` cancer (`AUC 0.78 vs 0.64` for total PSA alone).12 In a systematic review (`Pagniez et al., J Urol 2020`), pairing a negative MRI with `PSAD < 0.15 ng/mL/cc` raised the negative predictive value for clinically significant cancer from `84.4%` to `90.4%` (and up to `94%` in `AUA 2026` guideline series), though continued PSA monitoring is still essential (`5.5%` 7-year `GG >= 2` incidence in `GÖTEBORG-2` even when `PSAD < 0.10`).<a href="#ref-1" class="underline decoration-1 underline-offset-2 text-brand-primary hover:text-brand-primary transition-colors">12829

A traditional transrectal (`TRUS`) biopsy passes the needle through the rectal wall, carrying a `5% to 7%` infection risk and a `0.3% to 9.4%` sepsis risk across clinical series.30 A transperineal biopsy passes the needle through sanitized skin on the perineum, cutting post-biopsy sepsis by 84% (`RR 0.16`) in a 2026 meta-analysis (`Calpin et al., BJU Int 2026`) while matching or improving detection of anterior prostate tumors (`TRANSLATE` RCT, `Bryant et al., Lancet Oncology 2025`).3031

Ready when you are

Start your intake

The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.

TL;DR30-second take

TL;DR: Seeing a high PSA on your lab report is stressful, yet a single high reading is frequently not cancer. Across large studies, 22% to 38% of high PSAs drop back to normal on the next blood draw. Before anyone talks about a prostate biopsy, follow this 4-step triage sequence (AUA 2026, EAU 2026, and NCCN 2026 guidelines):

Check whether a medication is masking an even higher number (the 5-ARI rule): If you take finasteride (1 mg for hair loss or 5 mg for BPH) or dutasteride (0.5 mg), your printed PSA is cut in half (~40% to 50%). You must double your printed PSA before comparing it against our age cutoffs (< 2.5 ng/mL under age 60; < 4.0 ng/mL at age 60+), and evaluate any confirmed rise (>= 0.3 ng/mL) above your lowest on-treatment number.

Repeat the PSA in 4 to 8 weeks after a 48-hour washout (and skip empiric antibiotics): Abstain from ejaculation for 48 hours before the draw (and take 48 hours off heavy cycling or pelvic pressure as a zero-cost precaution). If you had a recent UTI or prostatitis, wait 6 to 8 weeks after it clears. Guidelines explicitly advise against taking antibiotics for a symptom-free high PSA.

Add Percent Free PSA (%fPSA) on the repeat draw: When total PSA is 4 to 10 ng/mL, a free PSA ratio above 25% drops cancer probability to 8%, whereas a ratio of 10% or under raises it to 56%.

Use a 3-Tesla prostate MRI + PSA density (PSAD < 0.15 ng/mL/cc) before any biopsy: If your repeat PSA stays high, an MRI-first workup (PRECISION and GÖTEBORG-2 trials) lets 25% to 50% of men avoid a biopsy, cuts harmless Grade Group 1 overdiagnosis in half, and targets the biopsy if one is needed.

What does a high PSA number mean for your risk?

Standard lab reports flag PSA at 4.0 ng/mL regardless of age, which misses how strongly healthy PSA levels depend on your decade of life:

In your 40s and 50s (Malmö Preventive Project, Vickers et al., BMJ 2013, n = 21,277): The population median PSA is 0.68 ng/mL at ages 45 to 49, 0.85 ng/mL at ages 51 to 55, and ~1.0 ng/mL at age 60.² ³ Men in the highest 10% (>= 1.6 ng/mL at ages 45 to 49, or >= 2.4 ng/mL at ages 51 to 55) account for 44% of all future prostate cancer deaths.²
Fishtown Medicine's age-adjusted cutoffs: Because 4.0 ng/mL is too loose for a man in his 40s or 50s, Fishtown Medicine uses a target of under 2.5 ng/mL for men under age 60 and under 4.0 ng/mL at age 60 and older.¹
What a PSA between 4 and 10 ng/mL means: Historically, a single PSA between 4 and 10 ng/mL carried roughly a 25% to 35% chance of finding any prostate cancer on biopsy, and more than half of those findings were slow-growing Grade Group 1 (Gleason 6) tumors that never would have threatened the man's life.¹ ⁴

What raises (or falsely lowers) PSA besides prostate cancer?

Before assuming a high PSA comes from a tumor, we check five non-cancer factors that move the number, including one common medication class that hides a high PSA in plain sight:¹

Factor	Quantified Effect on `PSA` in Clinical Studies	Practical Rule Before Your Next Draw
Febrile UTI or acute prostatitis (`Ulleryd 1999`; `Zackrisson 2003`)	Raises PSA 5- to 7-fold in `71% to 83%` of cases; can stay high with a low free/total ratio for up to 6 months.⁵ ⁶	Never test PSA during a urinary infection. Wait 6 to 8 weeks after an infection resolves. Do not take empiric antibiotics for an asymptomatic high PSA (`AUA 2026`).¹
Recent ejaculation (`Tchetgen et al., Urology 1996`)	Raises PSA by a mean `+41%` at 1 hour; returns to baseline in `92%` of men by 24 hours and `97%` by 48 hours (the `AUA` notes average population changes of `~10%`).¹ ⁷	Abstain from ejaculation for 48 hours before your blood draw.¹ ⁷
Prostate biopsy, TURP, or catheterization (`Oesterling 1993`; `Wong et al., World J Urol 2026` SR)	Biopsy or TURP raises PSA by a median `5.9 to 7.9 ng/mL` for `4+` weeks; urethral catheterization adds `+0.69 ng/mL` (`+0.28` without retention).⁸ ⁹	Wait at least 6 weeks after a biopsy/TURP and 2 to 6 weeks after catheter removal.⁸ ⁹ (A routine finger exam / `DRE` adds only `+0.4 ng/mL`, which is clinically trivial unless measuring free PSA.)¹⁰
Vigorous cycling or pelvic pressure (`Jiandani et al., 2015` meta-analysis, `n = 912`; `Lunacek 2022` RCT)	Pooled change across 6 studies was `+0.027 ng/mL` (`P = 0.74`), much smaller than once thought, and the `AUA 2026` guideline notes cycling does not appreciably alter PSA.¹ ¹¹	While cycling rarely explains a high PSA on its own, skipping heavy bike rides or marathon saddle time for 48 hours before a repeat draw is an easy, zero-cost precaution.¹
Benign prostate enlargement (`BPH`)	More benign gland tissue leaks more baseline PSA into the blood with age.	Separated from cancer risk by calculating PSA density (`PSAD = PSA / gland volume < 0.15 ng/mL/cc`) on ultrasound or MRI.¹ ¹²
Finasteride (`1 mg` hair loss / `5 mg` BPH) & Dutasteride (`0.5 mg`) (`PCPT`, `REDUCE`, `D'Amico 2007`)	Cuts PSA in half (`-40% to -50%`) after 6 to 12 months by shrinking gland tissue and blocking `DHT` gene transcription.¹³ ¹⁴ ¹⁵	Multiply your printed PSA by `2.0x` (`x2.3 to 2.5` after 7+ years on finasteride) AND evaluate any confirmed rise `>= 0.3 ng/mL` above your lowest on-treatment number (`nadir`).¹³ ¹⁶ ¹⁷

Why hair-loss finasteride (`1 mg`) is the most dangerous blind spot on a PSA report

How should you repeat a high PSA test?

Why? Because spontaneous year-to-year and month-to-month biological fluctuation is huge:

Memorial Sloan Kettering (Eastham et al., JAMA 2003): 30% of men with a PSA above 4.0 ng/mL had a normal PSA on their next test, and 44% normalized at some point over 4 years.²⁰
PLCO Trial (Pickersgill et al., JAMA Oncology 2025): 22% to 30% of values above threshold fell back below it within 1 year.²¹
PROBASE Trial (Krilaviciute et al., Eur Urol 2026): Among 45-year-old men, 38% normalized on confirmatory testing.²²
STHLM3 Trial: 17% of men with a PSA between 3 and 10 ng/mL dropped below 3.0 ng/mL within 8 weeks.¹

Your 4-point checklist for the repeat blood draw

Wait 4 to 8 weeks (or 6 to 8 weeks if you recently finished treatment for a UTI or prostatitis, or had a catheter/procedure).¹ ⁵
Abstain from ejaculation for 48 hours before the blood draw, and skip heavy cycling or intense workouts for 48 hours as a simple precaution.¹ ⁷
Ask your doctor to order Total PSA + Percent Free PSA (%fPSA) on the same tube (at the same lab chain, Quest or LabCorp, so the assay calibration matches).
If the repeat PSA drops back below target, do not disappear from follow-up: In longitudinal tracking (Connolly et al., 2008), roughly 25% of men whose PSA fell back below 4.0 ng/mL were eventually diagnosed with prostate cancer on later draws.²³ If your repeat normalizes, we recheck PSA in 6 to 12 months to confirm it stays down.

Fishtown Medicine

A 90-minute conversation with Dr. Ash. A written plan you can follow.

Start your intake

What happens if your repeat PSA stays high (`%fPSA`, `PSAD`, and `MRI`)?

Percent Free PSA (%fPSA, Catalona et al., JAMA 1998): Prostate cancer cells bind more PSA to blood proteins (ACT), leaving a smaller percentage of "free" (unbound) PSA floating in the bloodstream. For men with a total PSA between 4 and 10 ng/mL and a normal exam, cancer probability is 56% when %fPSA <= 10%, versus only 8% when %fPSA > 25% (AUC 0.72 vs 0.53 for total PSA alone, avoiding 20% of biopsies at 95% sensitivity; note that a 25% cutoff is less sensitive in Black men, Fowler 2000).²⁴ ²⁵ Crucially, %fPSA is not altered by finasteride or dutasteride.¹⁷
3-Tesla Prostate MRI (PROMIS, PRECISION, GÖTEBORG-2): Instead of sampling the gland blindly, a prostate MRI looks for discrete lesions and grades them from 1 (very low suspicion) to 5 (very high suspicion).⁴²⁶²⁷ Across randomized trials (high certainty for reducing biopsies and GG1 overdiagnosis; moderate certainty for GG >= 2 detection):
- In PRECISION (Kasivisvanathan et al., NEJM 2018, n = 500), MRI first allowed 28% of men to avoid biopsy, cut overdiagnosis of indolent Grade Group 1 (Gleason 6) tumors by 59% relative (9% vs 22%, -13 percentage points absolute), and caught more aggressive Grade Group >= 2 tumors (38% vs 26%, +12 percentage points absolute).⁴
- In GÖTEBORG-2 (Hugosson et al., NEJM 2024, n = 17,980, 4-year follow-up), MRI triage reduced biopsy indications by 59% to 74% and cut Grade Group 1 overdiagnosis by 57% (RR 0.43).²⁷
PSA Density (PSAD < 0.15 ng/mL/cc): Using the prostate volume measured on your MRI, we divide your total PSA by gland volume (ng/mL/cc). When a negative MRI (PI-RADS 1-2) is combined with a PSAD < 0.15 ng/mL/cc, the negative predictive value for clinically significant (GG >= 2) cancer climbs from 84.4% to 90.4% to 94% (Pagniez et al., J Urol 2020; AUA 2026), allowing up to two-thirds of men with a negative MRI to safely skip immediate biopsy while staying on regular PSA monitoring (GÖTEBORG-2 showed a 5.5% 7-year GG >= 2 incidence after a negative MRI with PSAD < 0.10, versus 11.9% to 13.8% when PSAD was higher).¹ ²⁸ ²⁹
Transperineal Targeted Biopsy (when biopsy is needed): If your MRI shows a PI-RADS 4 or 5 lesion (or PI-RADS 3 with high PSAD), we coordinate an MRI-targeted biopsy with in-network urology and favor the transperineal approach over the older transrectal approach. Across randomized trials (TRANSLATE, Bryant et al., Lancet Oncol 2025) and a 2026 meta-analysis (Calpin et al., BJU Int 2026), transperineal biopsy lowers post-biopsy sepsis risk by 84% (RR 0.16) (1.0% vs 1.4% sepsis readmission vs 5% to 7% historical transrectal infection rates, with a minor 1.9% vs 1.0% temporary urinary retention trade-off).³⁰ ³¹

Guidance from the Clinic

Key Takeaways

Roughly `22% to 38%` of high PSAs return to normal on repeat testing (`Eastham JAMA 2003`; `PROBASE 2026`), so always repeat an unexpected high reading in 4 to 8 weeks before jumping to biopsy.²⁰ ²²
Abstain from ejaculation for 48 hours before your repeat draw (`+41%` 1-hour rise) and wait 6 to 8 weeks after any UTI or prostatitis (`5- to 7-fold` rise); never take empiric antibiotics for a symptom-free high PSA.¹ ⁵ ⁷
Finasteride (`1 mg` hair loss or `5 mg` BPH) and dutasteride (`0.5 mg`) cut PSA by `~40% to 50%`: Double your printed PSA (`x2.0`, or `x2.3 to 2.5` after 7+ years) and evaluate any confirmed rise `>= 0.3 ng/mL` above your on-treatment nadir.¹³ ¹⁴ ¹⁶ ¹⁷
Use Percent Free PSA (`%fPSA`), PSA Density (`PSAD < 0.15 ng/mL/cc`), and 3-Tesla MRI before biopsy (`PRECISION`, `GÖTEBORG-2`): Spares `25% to 50%` of men from biopsy and cuts `Grade Group 1` overdiagnosis in half.⁴ ²⁴ ²⁷ ²⁸

PSA and Prostate Cancer Screening - midlife baseline medians (0.68 at age 45-49), ERSPC 23-year mortality data, and who should screen early
Enlarged Prostate (BPH) - treating urinary symptoms and understanding how 5-ARIs change PSA
Why We Choose an MRI - what a multiparametric prostate MRI involves
Paying Cash for Care - why doing the inexpensive repeat PSA draw first saves thousands on unnecessary imaging
Metabolic Health Beyond A1c - how insulin resistance links to prostate enlargement and aggressive disease